Global Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Landscape Professional Research Report 2024

Report Format: PDF   |   Report ID: 5685598   |   Published Date: August 2024   |   Pages:  170+  

Research Summary
Duchenne Muscular Dystrophy (DMD) drugs are medications specifically developed to address the symptoms and underlying causes of DMD, a genetic disorder characterized by progressive muscle degeneration and weakness. These drugs may include corticosteroids, which can help slow muscle deterioration and delay the loss of function. Emerging treatments encompass gene therapies designed to correct or replace the faulty dystrophin gene responsible for DMD, potentially offering more targeted and transformative approaches to managing the disease. DMD drugs aim to improve muscle function, mobility, and overall quality of life for individuals affected by this condition, representing significant advancements in the medical management of DMD.
According to DIResearch's in-depth investigation and research, the global Duchenne Muscular Dystrophy (DMD) Therapeutics market size will reach US$ XX Million in 2024, and is expected to reach US$ XX Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be US$ XX Million, accounting for approximately XX% of the world. It is expected to reach US$ XX Million in 2030, and the global share will reach XX%.
The major global manufacturers of Duchenne Muscular Dystrophy (DMD) Therapeutics include Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.
This report studies the market size, price trends and future development prospects of Duchenne Muscular Dystrophy (DMD) Therapeutics. Focus on analysing the market share, product portfolio, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market. The report data covers historical data from 2019 to 2023, base year in 2024 and forecast data from 2025 to 2030.
The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Duchenne Muscular Dystrophy (DMD) Therapeutics market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Duchenne Muscular Dystrophy (DMD) Therapeutics industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Duchenne Muscular Dystrophy (DMD) Therapeutics Include:
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Duchenne Muscular Dystrophy (DMD) Therapeutics Product Segment Include:
Exondys
 Emflaza
 Translarna
Duchenne Muscular Dystrophy (DMD) Therapeutics Product Application Include:
Hospitals
  Clinics
 Home Care
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends
Chapter 2: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Industry PESTEL Analysis
Chapter 3: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Porter's Five Forces Analysis
Chapter 4: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Major Regional Market Size and Forecast Analysis
Chapter 5: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast by Type and Application Analysis
Chapter 6: North America Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 7: Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 8: China Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 9: APAC (Excl. China) Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 10: Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 11: Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 12: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers
Chapter 15: Research Findings and Conclusion
Chapter 16: Methodology and Data Sources
Table of Contents

1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview

1.1 Product Definition and Statistical Scope

1.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product by Type

1.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type, 2023 VS 2024 VS 2030

1.2.2 Exondys

1.2.3  Emflaza

1.2.4  Translarna

1.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Product by Application

1.3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application, 2023 VS 2024 VS 2030

1.3.2 Hospitals

1.3.3   Clinics

1.3.4  Home Care

1.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue Analysis (2019-2030)

1.5 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Development Status and Trends

1.5.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Development Status Analysis

1.5.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Development Trends Analysis

2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market PESTEL Analysis

2.1 Political Factors Analysis

2.2 Economic Factors Analysis

2.3 Social Factors Analysis

2.4 Technological Factors Analysis

2.5 Environmental Factors Analysis

2.6 Legal Factors Analysis

3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Porter's Five Forces Analysis

3.1 Competitive Rivalry

3.2 Threat of New Entrants

3.3 Bargaining Power of Suppliers

3.4 Bargaining Power of Buyers

3.5 Threat of Substitutes

4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis by Regions

4.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Overall Market: 2023 VS 2024 VS 2030

4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Forecast Analysis (2019-2030)

4.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Market Share by Region (2019-2024)

4.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Forecast by Region (2025-2030)

5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type and Application

5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type

5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application

6 North America

6.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate Analysis (2019-2030)

6.2 North America Key Manufacturers Analysis

6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type

6.4 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application

6.5 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country

6.5.1 US

6.5.2 Canada

7 Europe

7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate Analysis (2019-2030)

7.2 Europe Key Manufacturers Analysis

7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type

7.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application

7.5 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country

7.5.1 Germany

7.5.2 France

7.5.3 United Kingdom

7.5.4 Italy

7.5.5 Spain

7.5.6 Benelux

8 China

8.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate Analysis (2019-2030)

8.2 China Key Manufacturers Analysis

8.3 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type

8.4 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application

9 APAC (excl. China)

9.1 APAC (excl. China) Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate Analysis (2019-2030)

9.2 APAC (excl. China) Key Manufacturers Analysis

9.3 APAC (excl. China) Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type

9.4 APAC (excl. China) Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application

9.5 APAC (excl. China) Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country

9.5.1 Japan

9.5.2 South Korea

9.5.3 India

9.5.4 Australia

9.5.5 Indonesia

9.5.6 Vietnam

9.5.7 Malaysia

9.5.8 Thailand

10 Latin America

10.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate Analysis (2019-2030)

10.2 Latin America Key Manufacturers Analysis

10.3 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type

10.4 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application

10.5 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country

10.5.1 Mecixo

10.5.2 Brazil

11 Middle East & Africa

11.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate Analysis (2019-2030)

11.2 Middle East & Africa Key Manufacturers Analysis

11.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type

11.4 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application

11.5 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country

11.5.1 Saudi Arabia

11.5.2 South Africa

12 Market Competition by Manufacturers

12.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue by Key Manufacturers (2020-2024)

12.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Landscape Analysis and Market Dynamic

12.2.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Landscape Analysis

12.2.2 Global Key Manufacturers Headquarter and Key Area Sales

12.2.3 Market Dynamic

13 Key Companies Analysis

13.1 Sarepta Therapeutics

13.1.1 Sarepta Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

13.1.2 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio

13.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)

13.2 PTC Therapeutics

13.2.1 PTC Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

13.2.2 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio

13.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)

13.3 Pfizer

13.3.1 Pfizer Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

13.3.2 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio

13.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)

13.4 Bristol-Myers Squibb

13.4.1 Bristol-Myers Squibb Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

13.4.2 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio

13.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)

13.5 Italfarmaco

13.5.1 Italfarmaco Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

13.5.2 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio

13.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)

13.6 Santhera Pharmaceuticals

13.6.1 Santhera Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

13.6.2 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio

13.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)

14 Industry Chain Analysis

14.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Chain Analysis

14.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Raw Material and Suppliers Analysis

14.2.1 Upstream Key Raw Material Supply Analysis

14.2.2 Raw Material Suppliers and Contact Information

14.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Typical Downstream Customers

14.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Channel Analysis

15 Research Findings and Conclusion

16 Methodology and Data Source

16.1 Methodology/Research Approach

16.2 Research Scope

16.3 Benchmarks and Assumptions

16.4 Date Source

16.4.1 Primary Sources

16.4.2 Secondary Sources

16.5 Data Cross Validation

16.6 Disclaimer


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Publisher: DIResearch
Choose License
Related Reports

Why Market Study Report?


  • Best Price for Reports
  • Large Report Database
  • Easily Customize Reports
  • 24/7 Email & Phone Support